Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities:
Net loss	$ (6,856)	$ (6,702)
Loss from discontinued operations	(1,370)	(2,362)
Loss from continuing operations	(5,486)	(4,340)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	570	45
Stock-based compensation expense	628	354
Loss on disposition of property & equipment	0	1
Board fees paid with common stock	113	0
Change in fair value of common stock warrants	159	(1,122)
Non-cash expense of issuing shares to Aspire Capital	602	0
Change in operating assets and liabilities:
Accounts receivable	0	(2)
Inventory	(163)	(670)
Prepaid expenses and other assets	1	12
Accounts payable	270	78
Accrued compensation and other current liabilities	(193)	(373)
Other long-term liabilities	(20)	64
Net cash used in continuing operating activities	(3,519)	(5,953)
Net cash used in discontinued operating activities	(1,428)	(2,070)
Net cash used in operating activities	(4,947)	(8,023)
Cash flows from investing activities:
Costs of Essentialis acquisition paid	(223)	0
Purchase of property and equipment	(4)	(20)
Net cash used in continuing investing activities	(227)	(20)
Net cash used in discontinued investing activities	(5)	(19)
Net cash used in investing activities	(232)	(39)
Cash flows from financing activities:
Proceeds from issuance of common stock	10,000	70
Net cash provided by continuing financing activities	10,000	5,070
Net cash provided by discontinued financing activities	0	0
Net cash provided by financing activities	10,000	5,070
Net increase (decrease) in cash and cash equivalents	4,821	(2,993)
Cash and cash equivalents, beginning of period	2,726	5,495
Cash and cash equivalents, end of period	7,547	2,502
Supplemental disclosures of noncash investing and financing information
Conversion of Series A preferred to common stock	0	2,220
Issuance of common stock in Essentialis acquisition	18,764	0
Costs of Essentialis acquisition included in accounts payable	349	0
Contingent consideration of Essentialis acquisition	1,090	0
Series A Convertible Preferred Stock [Member]
Cash flows from financing activities:
Proceeds from sale of Series A preferred convertible stock	0	5,071
Series A preferred convertible stock transaction costs paid	0	(71)
Series B Convertible Preferred Stock [Member] | Cash Less Exercise [Member]
Supplemental disclosures of noncash investing and financing information
De-recognition of Series B warrant liability (cashless exercise)	0	593
Continuing Operations [Member]
Cash flows from financing activities:
Net increase (decrease) in cash and cash equivalents	6,254	(967)
Discontinued Operations [Member]
Cash flows from financing activities:
Net increase (decrease) in cash and cash equivalents	$ (1,433)	$ (2,026)